Hemogenyx Pharmaceuticals PLC Collaboration with major US biotechnology company (4886H)
March 13 2018 - 2:01AM
UK Regulatory
TIDMHEMO
RNS Number : 4886H
Hemogenyx Pharmaceuticals PLC
13 March 2018
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Collaboration with major US biotechnology company
Collaboration to further develop humanized mice as a tool for
drug development and testing
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology
company developing novel therapies to transform bone marrow, or
blood stem cell, transplantation for the treatment of blood
diseases, announces that it has entered into a collaboration with
major US biotechnology company in a deal worth up to approximately
$250,000 for Hemogenyx.
The collaboration follows on from the announcement made by the
Company on 26 February 2018, which confirmed the filing of a
provisional patent application relating to the Company's
development of a new type of humanized mice with a chimeric
mouse-human blood system. These new humanized mice can be used for
disease modelling and drug development.
This application of Hemogenyx's humanized mice as a tool for
drug development and testing forms the basis of the Company's
collaboration with the US biotech company. The collaboration, which
is expected to last between four to six months, is a continuation
of work previously undertaken in partnership with the company, and
has the potential to generate further income as the collaboration
develops.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx,
commented: "We are pleased to collaborate with a major US
biotechnology company, a leader in the field of blood cancer
treatment. As we mentioned in our previous announcement, our new
type of humanized mice let us extend our work into other disease
models and specific drug development. The advancement of this
collaboration and potential future collaborations serve both as a
validation of our technology and a means of support for the further
development of our CDX bi-specific antibody product candidate."
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Via Walbrook PR
Executive Officer & Co-Founder
Dr Robin Campbell, Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137
1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186
9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Tel: +44 (0)20 7469
Limited 0930
Lucy Williams, Duncan Vasey
Walbrook PR Tel: +44 (0)20 7933 8780 or
hemogenyx@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned U.S. operating
subsidiary, HemoGenyx LLC, located in its state-of-the-art research
facility in Brooklyn, New York. HemoGenyx is a preclinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapies and treatments for blood
diseases such as leukemia and lymphoma. The company's leading
technologies aim to change the way in which bone
marrow/hematopoietic stem cell (BM/HSC) transplants are performed
and improve their efficacy. HemoGenyx's two distinct and
complementary products include an immunotherapy product for patient
conditioning-the CDX bi-specific antibody-and a cell therapy
product for BM/HSC transplantation-the HuPHEC. Each of these
products holds the potential to revolutionize the way BM/HSC
transplants are being performed, offering solutions that mitigate
the dangers and limitations associated with the current standard of
care. For more information, visit www.hemogenyx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAADAFFKPEAF
(END) Dow Jones Newswires
March 13, 2018 03:01 ET (07:01 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024